SCHEMBL2289607

SCHEMBL2289607

CCc1cc(OC)cc(OCC(N)=O)c1-c1nc2c(F)cc(F)cn2c1Nc1c(C)cccc1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.39
GAA P10253 13/20 0.39
TP53 P04637 7/20 0.37
THRB P10828 2/20 0.37
ZAP70 P43403 1/20 0.33
KARS1 Q15046 1/20 0.33
PTGER2 P43116 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
TPH1 P17752 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32
P2RX7 Q99572 1/20 0.32
PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288535 0.94 ZAP70 (0.32) MAPTGAAZAP70KARS1TPH1
SCHEMBL2287588 0.93 MAPT (0.37) MAPTGAATP53THRBZAP70
SCHEMBL2287599 0.88 GAA (0.41) MAPTGAATP53THRBKDM4E
SCHEMBL2289661 0.87 MAPT (0.40) MAPTGAATP53THRBKDM4E
SCHEMBL2288199 0.87 MAPT (0.41) MAPTGAATP53THRBPTGER2
SCHEMBL2292747 0.86 P2RX7 (0.33) ZAP70KARS1P2RX7
SCHEMBL2292328 0.86 FFAR1 (0.35) GAAKDM4ESMN1; SMN2P2RX7
SCHEMBL2288751 0.86 MAPT (0.35) MAPTGAATP53THRBPTGER2
SCHEMBL2295061 0.85 MAPT (0.40) MAPTGAATP53THRBTPH1
SCHEMBL2290761 0.84 MAPT (0.41) MAPTGAATP53THRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885GAA 1202/4885TP53 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.